Medpace Holdings, Inc. $MEDP Shares Newly Purchased by Monument Capital Management

Monument Capital Management purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 4,668 shares of the company’s stock, valued at approximately $2,914,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. American Capital Management Inc. acquired a new stake in shares of Medpace during the 2nd quarter worth $111,329,000. The Manufacturers Life Insurance Company purchased a new stake in Medpace during the second quarter valued at about $10,615,000. Focus Partners Advisor Solutions LLC purchased a new position in shares of Medpace in the 2nd quarter worth about $1,685,000. California State Teachers Retirement System raised its holdings in shares of Medpace by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after purchasing an additional 4,719 shares during the period. Finally, Rice Hall James & Associates LLC purchased a new position in shares of Medpace in the 2nd quarter worth about $28,659,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on MEDP shares. Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. BMO Capital Markets lifted their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. TD Cowen boosted their price objective on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Finally, Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $607.73.

Insider Activity

In other news, CEO August Troendle sold 21,966 shares of the business’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the transaction, the chief executive officer directly owned 338,225 shares of the company’s stock, valued at approximately $211,549,590.75. The trade was a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 336,140 shares of company stock worth $208,008,328 in the last 90 days. Company insiders own 20.50% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $602.70 on Friday. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The company has a market capitalization of $16.82 billion, a price-to-earnings ratio of 35.33, a PEG ratio of 2.70 and a beta of 1.18. The business has a 50-day moving average of $602.08 and a 200-day moving average of $525.93.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% on a year-over-year basis. During the same period last year, the business posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.